Adamed Group
Company overview
strony wersji drukowanej: 14-16




ADAMED GROUP, privately-held pharmaceutical company established in 1986, in the past 25 years has become one of the leaders of Polish pharmaceutical market. Today our product portfolio consists of internationally marketed Rx & OTC drugs, dietary supplements and skincare products.

1. Research & development
In 2001 we pioneered drug discovery within the Polish pharmaceutical industry. Throughthe years we have built modern laboratory facilities and have attracted leading scientists from Polish academia. We have launched multiple research programs that seek innovative small-molecule and biologic drug candidates for cancer, metabolic disorders and central nervous system diseases. The drug candidates are intended for early-stage out-licensing.

1.1 Oncology
Each year there are over 10 million people diagnosed with cancer worldwide. Although the technology and understanding of cancer advance at remarkable pace, still the effective treatment of many tumor types stays beyond our reach. Together with the emergence of targeted therapies there came into view new hope for an effective treatment for the suffering.

Our research in oncology focuses on discovery and development of recombinant proteins for treatment of solid tumors. The molecules utilize cancer specific targeting carrier that is used to deliver a broad array of cytotoxic signals to tumor environment. In-vitro assays indicate the molecules possess potent anticancer activity achieved at picomolar concentrations, while being nontoxic on human hepatocytes. Furthermore they selectively exhibit cytotoxic activity between cancer and normal cells of the same tissue. In-vivo studies show tumor remission or reduction activity in xenograft models of difficult to treat human tumorsincluding lung, pancreatic or colon cancers. The program is currently at preclinical stage.

1.2 CNS diseases
The CNS therapeutic area covers various diseases that together account for 35% of total disease burden on seven major markets. One of the major diseases that we are focused on is schizophrenia that is associated with the socio-environmental changes related with industrial growth. Despite the significant unmet medical need for the last 10 years there has been no major breakthrough discovery that would considerably improve the quality of lives of the patients.

Our CNS research focuses on discovery and development of potent antipsychotic drugs for treatment of schizophrenia and other CNS diseases. Our lead candidates possess unique receptor profiles that translate into better efficacy and safety than current standards of treatments. The molecules are characterized by lower side effects thanthose of current treatments, significant enhancement of cognitive functions and additional antidepressive and anxiolytic effects. The program is currently at preclinical stage.

1.3 Metabolic disorders
Due to the unhealthy sedentary lifestyle the epidemic of the 21st century is said to be the type II diabetes. The patient population is estimated to reach 300 million people. The incidence of this disease is forecasted to double within the next 20 years, what makes diabetes one of the main challenges of contemporary medicine. The range of an unmet medical need involves diagnostics, prevention of the disease progression, reducing patient weight and the treatment of diabetes complications.

Our research in metabolism focuses on discovery of mitochondria-based therapiesfor treatment of metabolic disorders. In-vitro results of our most promising compounds demonstrate significant changes in various parameters related to mitochondrial energy metabolism e.g. substantial increase in UCP content, slight rise in total mitochondrial mass and increased insulin sensitivity. The program is currently at the discovery stage.



2 Laboratories
Our main research facility is located at the suburbs of Warsaw, in close proximity to Kampinos National Park. The neighborhood provides clean, quiet and undisturbed conditions for conducting research. The facility, which accommodates about 80 scientists, is divided into chemical and biology divisions. The Chemical Laboratory conducts synthesis of new chemical compounds with the potential for future application as innovative drugs. The Biology Laboratory, comprising of In-silico Laboratory, General Laboratory, Biotechnology Laboratory, Radioisotopes Laboratory and Animal Facility – all equipped with the cutting edge technology and latest generation equipment, is used to conduct researchwhich combines biochemistry, physiology, molecular biology and biotechnology. Research of our scientists is supported by our in-house patenting attorneys, who oversee the discovery process on a daily basis.



3 Cooperation & contact
At ADAMED GROUP we are committed to forming partnerships with leading universities, research institutes and scientists. Our goal is to create an environment, where scientists from various fields – including medicine, biology, pharmacy, biotechnology, chemistry and engineering – openly exchange their ideas and expertise. For this reason all of our research programs involve collaborations with best research centres in Poland and abroad, as well as with renowned CROs. Since drug discovery is our priority, we are constantly looking for opportunities to strengthen our network of collaborations and areas of activity. Always appreciating the best ideas in drug discovery, we create partner relations with scientists and institutions. For further information please visit our corporate website at http://www.adamed.com.pl/en/ or contact:

Łukasz Kalinowski
Head of Drug Discovery
ADAMED GROUP
Pienkow 149
05-152 Czosnow near Warsaw
e-mail:
Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie w przeglądarce obsługi JavaScript.

Jerzy Pieczykolan, Ph.D.
Head of Research Laboratory
ADAMED GROUP
Pienkow 149
05-152 Czosnow near Warsaw
e-mail:
Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie w przeglądarce obsługi JavaScript.